Newsletter Signup
Where current and emerging technology trends meet.
TecTrendsInformation Sources, Inc.
  | About TecTrends | Email Signup | Contact Us
 Live Search:
Live Search | Articles | Companies | TecTerms | Products
  Loading TecTrends Live Search - please wait... 
View Noteworthy Articles      PRNewswire
 
Article

Title: Waiting to Inhale

Author: Branca, Malorye A; Sannes, Lucy Article Type: Product Analysis
Source: Pharma DD, v1 n1 p10(1) Publication Date: Jul 2006
  ISSN: 1932-1953
URL of Publication: http://www.pharmadd.com

Pfizer's Exubera for type 1 and type 2 diabetes is the first Food and Drug Administration-approved inhaled insulin available in the market. Huge sales are predicted for the drug. However, issues on how patients and doctors will accept the product may arise. According to Pfizer, many clinical trials favor Exubera over insulin injections. One of the problems with inhaled drugs is obtaining a precise dose. It also has long-term safety questions that are yet to be answered. The drug will soon compete with Eli Lilly and Novo Nordisk. Novo Nordisk is partnering with Aradigm for an insulin drug. Both pharmaceutical companies have inhaled-type insulin products in the third stage of development. Researches reveal that type 2 diabetics do not get an early treatment because of injections. Accurate doses and gradual increases are necessary for the treatment. Nektar Therapeutics provides Pfizer the technology for Exubera. More inhaled protein products are being developed. Eli Lilly is working with Alkermes in developing inhalable human growth hormone and parathyroid hormone. Compared with the insulin product, these hormones are in earlier stages of development. Another company, Momenta Pharmaceutica, is also developing inhaled products--interferon beta, erythropoietin, insulin, and human growth hormone.

Companies:
Pfizer Inc

Products:
Exubera Medical Therapies

TecTerms:


[Get Copyright Permissions] Click here for copyright permissions!
Copyright 2004-2008 Information Sources Inc.
 


Home About TecTrends About Us Contact Us Privacy Statement Terms and Conditions

TecTrends | P.O. Box 8120 | Berkeley CA 94707 | (510) 525-6220 | Email: tectrends@tectrends.com
© 2006 INFORMATION SOURCES INC | All rights reserved.